Highlights

  • Underlying FY26 EBIT reached AUD 196.1 million, an increase of 24.4%.
  • Underlying net profit after tax rose 24.1% to AUD 144.7 million; reported profit was materially higher.
  • The company signed ten contracts with an aggregate disclosed value of at least AUD 407 million.
  • Six contract renewals totalled AUD 141 million, while implementation timing remains important.

Pro Medicus Ltd (ASX:PME) develops medical imaging software used by hospitals, imaging centres and healthcare groups, including its Visage platform for radiology workflows. Its FY26 result combined higher underlying Earnings with new customer contracts and renewals. The distinction between signed contract value and Revenue recognised during customer implementation is central to understanding the year's performance. The company also continued to develop products adjacent to its established imaging business.

Underlying profit and currency translation

Pro Medicus (ASX:PME) reported underlying earnings before interest and tax of AUD 196.1 million for FY26, 24.4% above the previous year. The underlying EBIT Margin reached 74.9%, approximately 90 basis points higher. Underlying net profit after tax increased 24.1% to AUD 144.7 million. These measures describe operating performance after adjustments identified by the company and should not be confused with statutory earnings.

Reported net profit after tax was AUD 265.3 million, up 130.3%. The difference from Underlying Profit is substantial; the statutory growth rate cannot be used as a substitute for growth in recurring operations. On a constant-currency basis, underlying net profit after tax was AUD 154.5 million, an increase of 32.5%. Currency therefore materially affected the reported comparison. The group earns considerable revenue outside Australia, particularly in the United States.

Contracts, renewals and implementation

During FY26, Pro Medicus (ASX:PME) signed ten contracts with an aggregate stated value of at least AUD 407 million and renewed six agreements valued at AUD 141 million. One of the new agreements was a ten-year arrangement with UC Health in Colorado. Contract values represent obligations over multiple years rather than revenue earned immediately.

The Visage Business uses transaction-linked pricing, often supported by minimum annual commitments. Consequently, the number of imaging studies processed after deployment matters alongside the headline value of each contract. Large hospitals can require lengthy system migration, testing and staff adoption before transaction volumes reach a normal operating level.

The Trinity Health implementation was described as largely complete during 2026. Management expects its contribution to become more fully reflected in FY27 activity. That expectation depends on actual customer volumes and the timing of final deployment stages. Renewals also matter because existing customers can choose alternative systems when contracts expire, even though replacing established clinical software may be operationally demanding.

Product development and competitive exposure

Pro Medicus (ASX:PME) has described plans to extend its technology into reporting tools and additional medical specialties, including cardiology and pathology. These initiatives differ in commercial Maturity from its established radiology platform. A planned product, trial or early implementation should not be treated as an established revenue stream.

The company also operates in a changing market for artificial intelligence in medical imaging. AI-enabled workflows could alter how clinicians review scans and how hospitals evaluate software. The commercial outcome is not yet settled: technology development creates opportunities for product additions but may also increase competition or customer demands for interoperability.

FY27 operating questions

For FY27, the relevant measures are realised transaction volumes, the timing of major customer implementations, new contract wins and renewal terms. Management's aspirations for growth should be distinguished from formal financial guidance. The FY26 underlying and statutory results provide different baselines, so subsequent comparisons should identify the earnings measure being used.

Key Insights

Pro Medicus (ASX:PME) increased underlying earnings in FY26 while adding and renewing long-duration contracts. The main operational test is how customer deployment schedules translate contract commitments into transaction revenue; product expansion and competition remain separate considerations.